Thomas, Neal J <br/><br/>
Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model.  [electronic resource] 

 -  Journal of pediatric hematology/oncology  Apr 2007 
 - 227-32 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1077-4114 
<br/><br/><label>Standard No.: </label>10.1097/MPH.0b013e3180437ded  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antiviral Agents--adverse effects<br/>Bone Marrow Transplantation<br/>Child<br/>Child, Preschool<br/>Decision Support Techniques<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Immunocompromised Host<br/>Infant<br/>Infant, Newborn<br/>Male<br/>Palivizumab<br/>Respiratory Syncytial Virus Infections--mortality<br/>Respiratory Syncytial Virus, Human<br/>Survival Rate<br/>Treatment Outcome